Pharmacological modulation of late radio-induced side effects;Modulation pharmacologique des effets tardifs de l'irradiation

Cancer/Radiotherapie

Volumn 15, Issue 5, 2011, Pages 383-389

  Bourgier, C ^a,b,c   Monceau, V ^a,b,c   Bourhis, J ^a,b,c   Deutsch, E ^a,b,c   Vozenin, M C ^a,b,c,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c Institut Gustave Roussy   (France)

^d Universite Paris Sud   (France)

Author keywords

Late effect; Pharmacomodulation; Radiotherapy; Sequelae

Indexed keywords

FIBROSIS; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION SICKNESS; RADIOTHERAPY; SHORT SURVEY; TOXICITY;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, RADIATION; EPIGENESIS, GENETIC; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INTEGRINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MESODERM; MYOBLASTS; NEOPLASM PROTEINS; OXIDATIVE STRESS; PROTEIN KINASE INHIBITORS; RADIATION INJURIES; RADIATION TOLERANCE; RADIOTHERAPY; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 79961211357     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2011.01.008     Document Type: Short Survey

References (99)

1. Barcellos-Hoff M.H. How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. Radiat Res 1998, 150:S109-S120.
2. Rodemann H.P., Blaese M.A. Responses of normal cells to ionizing radiation. Semin Radiat Oncol 2007, 17:81-88.
3. Denham J.W., Hauer-Jensen M. The radiotherapeutic injury: a complex 'wound'. Radiother Oncol 2002, 63:129-145.
4. Hovdenak N., Fajardo L.F., Hauer-Jensen M. Acute radiation proctitis: a sequential clinicopathologic study during pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2000, 48:1111-1117.
5. Holthusen H. Erfahrungen über die verträglichkeitsgrenze für röntgenstrahlen und deren nutzanwendung zur verhütung von schäden. Strahlentherapie 1936, 57:254-269.
6. Cosset J.M. Effets secondaires des rayonnements sur les tissus sains et organes à risque. Cancer Radiother 2010, 14:228-231.
7. Rubin P., Casarett G. Clinical radiation pathology 1968, Saunders, Philadelphia.
8. Withers H.C., Peters L.J., Kogelnick H.D. Radiation biology in cancer research 1980, Raven Press, New York.
9. Dorr W., Hendry J.H. Consequential late effects in normal tissues. Radiother Oncol 2001, 61:223-231.
10. Bentzen S.M., Overgaard J. Patient-to-patient variability in the expression of radiation-induced normal tissue injury. Semin Radiat Oncol 1994, 4:68-80.
11. Bristow R.G., Benchimol S., Hill R.P. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 1996, 40:197-223.
12. Morgan J.L., Holcomb T.M., Morrissey R.W. Radiation reaction in ataxia telangiectasia. Am J Dis Child 1968, 116:557-558.
13. Gatti R.A. The inherited basis of human radiosensitivity. Acta Oncol 2001, 40:702-711.
14. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003, 3:155-168.
15. Molla M., Gironella M., Miquel R., Tovar V., Engel P., Biete A., et al. Relative roles of ICAM-1 and VCAM-1 in the pathogenesis of experimental radiation-induced intestinal inflammation. Int J Radiat Oncol Biol Phys 2003, 57:264-273.
16. Molla M., Panes J. Radiation-induced intestinal inflammation. World J Gastroenterol 2007, 13:3043-3046.
17. Molla M., Panes J., Casadevall M., Salas A., Conill C., Biete A., et al. Influence of dose-rate on inflammatory damage and adhesion molecule expression after abdominal radiation in the rat. Int J Radiat Oncol Biol Phys 1999, 45:1011-1018.
18. Wynn T.A. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004, 4:583-594.
19. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002, 3:349-363.
20. Gabbiani G., Ryan G.B., Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 1971, 27:549-550.
21. Hinz B., Phan S.H., Thannickal V.J., Galli A., Bochaton-Piallat M.L., Gabbiani G. The myofibroblast. One function, multiple origins. Am J Pathol 2007, 170:1807-1816.
22. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214:199-210.
23. Sime P.J., O'Reilly K.M. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 2001, 99:308-319.
24. Willis B.C., duBois R.M., Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc 2006, 3:377-382.
25. Murphy K.M., Reiner S.L. The lineage decisions of helper T cells. Nat Rev Immunol 2002, 2:933-944.
26. Fajardo L.F. The endothelial cell is a unique target of radiation: an overview. The radiation biology of the vascular endothelium 1998, 1-13. CRC Press, Boca Raton, FL. D.B. Rubin (Ed.).
27. Law M.P. Radiation-induced vascular injury and its relation to late effects in normal tissues. Adv Radiat Biol 1981, 9.
28. Hallahan D., Clark E.T., Kuchibhotla J., et al. E-selectin gene induction by ionizing radiation is independent of cytokine induction. Biochem Biophys Res Commun 1995, 217:784-795.
29. Jahroudi N., Ardekani A.M., Greenberger J.S. Ionizing irradiation increases transcription of the von Willebrand factor gene in endothelial cells. Blood 1996, 88:3801-3814.
30. Rubin D.B., Drab E.A., Ts'ao C.H., Gardner D., Ward W.F. Prostacyclin synthesis in irradiated endothelial cells cultured from bovine aorta. J Appl Physiol 1985, 58:592-597.
31. Verheij M., Dewit L.G., van Mourik J.A. The effect of ionizing radiation on endothelial tissue factor activity and its cellular localization. Thromb Haemost 1995, 73:894-895.
32. Ward W.F., Kim Y.T., Molteni A., Solliday N.H. Radiation-induced pulmonary endothelial dysfunction in rats: modification by an inhibitor of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys 1988, 15:135-140.
33. Zhou Q., Zhao Y., Li P., Bai X., Ruan C. Thrombomodulin as a marker of radiation-induced endothelial cell injury. Radiat Res 1992, 131:285-289.
34. Giotopoulos G., Symonds R.P., Foweraker K., Griffin M., Peat I., Osman A., et al. The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br J Cancer 2007, 96:1001-1007.
35. Rodemann H.P., Peterson H.P., Schwenke K., von Wangenheim K.H. Terminal differentiation of human fibroblasts is induced by radiation. Scanning Microsc 1991, 5:1135-1142. [discussion 1142, 1133].
36. Bumann J., Santo-Holtje L., Loffler H., Bamberg M., Rodemann H.P. Radiation-induced alterations of the proliferation dynamics of human skin fibroblasts after repeated irradiation in the subtherapeutic dose range. Strahlenther Onkol 1995, 171:35-41.
37. Barcellos-Hoff M.H., Dix T.A. Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 1996, 10:1077-1083.
38. Jobling M.F., Mott J.D., Finnegan M.T., Jurukovski V., Erickson A.C., Walian P.J., et al. Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat Res 2006, 166:839-848.
39. Zheng H., Wang J., Koteliansky V.E., Gotwals P.J., Hauer-Jensen M. Recombinant soluble transforming growth factor beta type II receptor ameliorates radiation enteropathy in mice. Gastroenterology 2000, 119:1286-1296.
40. Anscher M.S., Thrasher B., Zgonjanin L., Rabbani Z.N., Corbley M.J., Fu K., et al. Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2008, 71:829-837.
41. Vozenin-Brotons M.C., Milliat F., Linard C., Strup C., François A., Sabourin J.C., et al. Gene expression profile in human late radiation enteritis obtained by high-density cDNA array hybridization. Radiat Res 2004, 161:299-311.
42. Shimizu Y., Dobashi K., Iizuka K., Horie T., Suzuki K., Tukagoshi H., et al. Contribution of small GTPase Rho and its target protein rock in a murine model of lung fibrosis. Am J Respir Crit Care Med 2001, 163:210-217.
43. Heusinger-Ribeiro J., Eberlein M., Wahab N.A., Goppelt-Struebe M. Expression of connective tissue growth factor in human renal fibroblasts: regulatory roles of RhoA and cAMP. J Am Soc Nephrol 2001, 12:1853-1861.
44. Nagatoya K., Moriyama T., Kawada N., Takeji M., Oseto S., Murozono T., et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002, 61:1684-1695.
45. Eberlein M., Heusinger-Ribeiro J., Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001, 133:1172-1180.
46. Murata T., Arii S., Nakamura T., Mori A., Kaido T., Furuyama H., et al. Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells. J Hepatol 2001, 35:474-481.
47. Bourgier C., Haydont V., Milliat F., François A., Holler V., Lasser P., et al. Inhibition of Rho kinase modulates radiation induced fibrogenic phenotype in intestinal smooth muscle cells through alteration of the cytoskeleton and connective tissue growth factor expression. Gut 2005, 54:336-343.
48. Haydont V., Bourgier C., Pocard M., Lusinchi A., Aigueperse J., Mathé D., et al. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clin Cancer Res 2007, 13:5331-5340.
49. Haydont V., Bourgier C., Vozenin-Brotons M.C. Rho/ROCK pathway as a molecular target for modulation of intestinal radiation-induced toxicity. Br J Radiol 2007, 80:S32-S40.
50. Haydont V., Gilliot O., Rivera S., Bourgier C., François A., Aigueperse J., et al. Successful mitigation of delayed intestinal radiation injury using pravastatin is not associated with acute injury improvement or tumor protection. Int J Radiat Oncol Biol Phys 2007, 68:1471-1482.
51. Haydont V., Mathe D., Bourgier C., Abdelali J., Aigueperse J., Bourhis J., et al. Induction of CTGF by TGF-beta1 in normal and radiation enteritis human smooth muscle cells: Smad/Rho balance and therapeutic perspectives. Radiother Oncol 2005, 76:219-225.
52. Demayo F., Minoo P., Plopper C.G., Schuger L., Shannon J., Torday J.S. Mesenchymal-epithelial interactions in lung development and repair: are modeling and remodeling the same process?. Am J Physiol Lung Cell Mol Physiol 2002, 283:L510-L517.
53. Lindroos P.M., Coin P.G., Badgett A., Morgan D.L., Bonner J.C. Alveolar macrophages stimulated with titanium dioxide, chrysotile asbestos, and residual oil fly ash upregulate the PDGF receptor-alpha on lung fibroblasts through an IL-1beta-dependent mechanism. Am J Respir Cell Mol Biol 1997, 16:283-292.
54. Mondy J.S., Lindner V., Miyashiro J.K., Berk B.C., Dean R.H., Geary R.L. Platelet-derived growth factor ligand and receptor expression in response to altered blood flow in vivo. Circ Res 1997, 81:320-327.
55. Zhang S., Smartt H., Holgate S.T., Roche W.R. Growth factors secreted by bronchial epithelial cells control myofibroblast proliferation: an in vitro co-culture model of airway remodeling in asthma. Lab Invest 1999, 79:395-405.
56. Bergsten E., Uutela M., Li X., Ostman A., Heldin C.H., Alitalo K., et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 2001, 3:512-516.
57. Li X., Ponten A., Aase K., Abramsson A., Uutela M., Bäckström G., et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2000, 2:302-309.
58. Zhuo Y., Zhang J., Laboy M., Lasky J.A. Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2004, 286:L182-L188.
59. Langberg C.W., Hauer-Jensen M., Sung C.C., Kane C.J. Expression of fibrogenic cytokines in rat small intestine after fractionated irradiation. Radiother Oncol 1994, 32:29-36.
60. Rubin K., Terracio L., Ronnstrand L., Heldin C.H., Klareskog L. Expression of platelet-derived growth factor receptors is induced on connective tissue cells during chronic synovial inflammation. Scand J Immunol 1988, 27:285-294.
61. Tada H., Ogushi F., Tani K., Nishioka Y., Miyata J.Y., Sato K., et al. Increased binding and chemotactic capacities of PDGF-BB on fibroblasts in radiation pneumonitis. Radiat Res 2003, 159:805-811.
62. Bonner J.C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004, 15:255-273.
63. Ingram J.L., Bonner J.C. EGF and PDGF receptor tyrosine kinases as therapeutic targets for chronic lung diseases. Curr Mol Med 2006, 6:409-421.
64. Abdollahi A., Li M., Ping G., Plathow C., Domhan S., Kiessling F., et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005, 201:925-935.
65. Andrae J., Gallini R., Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008, 22:1276-1312.
66. Kurmasheva R.T., Houghton P.J. IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 2006, 1766:1-22.
67. LeRoith D., Roberts C.T. The insulin-like growth factor system and cancer. Cancer Lett 2003, 195:127-137.
68. Choi J.E., Lee S.S., Sunde D.A., Huizar I., Haugk K.L., Thannickal V.J., et al. Insulin-like growth factor-I receptor blockade improves outcome in mouse model of lung injury. Am J Respir Crit Care Med 2009, 179:212-219.
69. Ai W, Zhang Y, Tang QZ, Bian ZY, Liu C, Huang H, et al. Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling. J Cell Biochem 2010;110:1111-22.
70. Baillet F., Housset M., Michelson A.M., Puget K. Treatment of radiofibrosis with liposomal superoxide dismutase. Preliminary results of 50 cases. Free Radic Res Commun 1986, 1:387-394.
71. Delanian S., Baillet F., Huart J., Lefaix J.L., Maulard C., Housset M. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. Radiother Oncol 1994, 32:12-20.
72. Duncan M.R., Hasan A., Berman B. Pentoxifylline, pentifylline, and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation. J Invest Dermatol 1995, 104:282-286.
73. Delanian S., Lefaix J.L. The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiother Oncol 2004, 73:119-131.
74. Delanian S., Porcher R., Balla-Mekias S., Lefaix J.L. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 2003, 21:2545-2550.
75. Delanian S., Porcher R., Rudant J., Lefaix J.L. Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. J Clin Oncol 2005, 23:8570-8579.
76. Martin M., Delanian S., Sivan V., Vozenin-Brotons M.C., Reisdorf P., et al. Radiation-induced superficial fibrosis and TGF-alpha 1. Cancer Radiother 2000, 4:369-384.
77. Delanian S., Chatel C., Porcher R., Depondt J., Lefaix J.L. Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a Phase II trial. Int J Radiat Oncol Biol Phys 2010, [Epub ahead of print]. http://dx.doi.org/10.1016/j.ijrobp.2010.03.029.
78. Delanian S., Lefaix J.L., Maisonobe T., Salachas F., Pradat P.F. Significant clinical improvement in radiation-induced lumbosacral polyradiculopathy by a treatment combining pentoxifylline, tocopherol, and clodronate (Pentoclo). J Neurol Sci 2008, 275:164-166.
79. Okunieff P., Augustine E., Hicks J.E., Cornelison T.L., Altemus R.M., Naydich B.G., et al. Pentoxifylline in the treatment of radiation-induced fibrosis. J Clin Oncol 2004, 22:2207-2213.
80. Gothard L., Cornes P., Brooker S., Earl J., Glees J., Hall E., et al. Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy. Radiother Oncol 2005, 75:334-341.
81. Gothard L., Cornes P., Earl J., MacLaren J., Mortimer P., Peacock J., et al. Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer. Radiother Oncol 2004, 73:133-139.
82. Laurent C., Pouget J.P., Voisin P. Modulation of DNA damage by pentoxifylline and alpha-tocopherol in skin fibroblasts exposed to Gamma rays. Radiat Res 2005, 164:63-72.
83. Laurent C., Voisin P., Pouget J.P. DNA damage in cultured skin microvascular endothelial cells exposed to gamma rays and treated by the combination pentoxifylline and alpha-tocopherol. Int J Radiat Biol 2006, 82:309-321.
84. Delanian S., Lefaix J.L., Housset M. La fibrose iatrogénique en cancérologie (2e partie): principales étiologies et possibilités thérapeutiques. Bull Cancer 1993, 80:202-212.
85. Geraci J.P., Mariano M.S., Jackson K.L. Amelioration of radiation nephropathy in rats by dexamethasone treatment after irradiation. Radiat Res 1993, 134:86-93.
86. Gross N.J., Holloway N.O., Narine K.R. Effects of some nonsteroidal anti-inflammatory agents on experimental radiation pneumonitis. Radiat Res 1991, 127:317-324.
87. Michalowski A.S. On radiation damage to normal tissues and its treatment. II. Anti-inflammatory drugs. Acta Oncol 1994, 33:139-157.
88. Mayer R., Klemen H., Quehenberger F., Sankin O., Mayer E., Hackl A., et al. Hyperbaric oxygen: an effective tool to treat radiation morbidity in prostate cancer. Radiother Oncol 2001, 61:151-156.
89. Pasquier D., Hoelscher T., Schmutz J., Dische S., Mathieu D., Baumann M., et al. Hyperbaric oxygen therapy in the treatment of radio-induced lesions in normal tissues: a literature review. Radiother Oncol 2004, 72:1-13.
90. Bickelhaupt S., Peschke P., Erbel C., Tietz A., Timke C., Wirkner U., et al. Attenuation and reversal of radiation-induced pulmonary fibrosis in a murine model by an Anti-CTGF monoclonal antibody. Int J Radiat Oncol Biol Phys 2010, 78:S40.
91. Gervaz P., Morel P., Vozenin-Brotons M.C. Molecular aspects of intestinal radiation-induced fibrosis. Curr Mol Med 2009, 9:273-280.
92. Monceau V, Pasinetti N, Schupp C, Pouzoulet F, Opolon P, Vozenin MC. Modulation of the Rho/ROCK Pathway in heart and lung after thorax irradiation reveals targets to improve normal tissue toxicity. Curr Drug Targets 2010;11:1395-404.
93. Gaugler M.H., Vereycken-Holler V., Squiban C., Vandamme M., Vozenin-Brotons M.C., Benderitter M. Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. Radiat Res 2005, 163:479-487.
94. Holler V., Buard V., Gaugler M.H., Guipaud O., Baudelin C., Sache A., et al. Pravastatin limits radiation-induced vascular dysfunction in the skin. J Invest Dermatol 2009, 129:1280-1291.
95. Shi J., Wang J., Zheng H., Ling W., Joseph J., Li D., et al. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 2003, 14:575-585.
96. Wang J., Boerma M., Fu Q., Hauer-Jensen M. Significance of endothelial dysfunction in the pathogenesis of early and delayed radiation enteropathy. World J Gastroenterol 2007, 13:3047-3055.
97. Wang J., Boerma M., Fu Q., Kulkarni A., Fink L.M., Hauer-Jensen M. Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism. Int J Radiat Oncol Biol Phys 2007, 68:1483-1490.
98. Williams J.P., Hernady E., Johnston C.J., Reed C.M., Fenton B., Okunieff P., et al. Effect of administration of lovastatin on the development of late pulmonary effects after whole-lung irradiation in a murine model. Radiat Res 2004, 161:560-567.
99. Toledano A., Garaud P., Serin D., Fourquet A., Bosset J.F., Miny-Buffet J., et al. La chimiothérapie concomitante de la radiothérapie augmente la toxicité tardive après chirurgie conservatrice du cancer du sein. Cancer Radiother 2006, 10:158-167.